Seeking Alpha

Impax Labs (IPXL -11%) takes a hit on the back of the FDA's approval of Actavis' generic version...

Impax Labs (IPXL -11%) takes a hit on the back of the FDA's approval of Actavis' generic version of Shire's Adderall XR. Jefferies says the approval means an immediate hit to FY12 - 14 revenue and lowers its price target from $21 to $20.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs